Impacto de la implementación de guías de práctica clínica en la mortalidad por enfermedad cardiovascular en Colombia, 2007-2023.
| dc.contributor.advisor | Montealegre Esmeral, Leslie | |
| dc.contributor.author | Pacheco Miranda, Fredy Javier | |
| dc.contributor.author | Orozco Álvarez, Lorena Rocío | |
| dc.coverage.spatial | Barranquilla | spa |
| dc.creator.email | fredypacheco99@gmail.com | spa |
| dc.creator.email | mdloreorozco@gmail.com | spa |
| dc.date.accessioned | 2025-07-18T15:20:07Z | |
| dc.date.available | 2025-07-18T15:20:07Z | |
| dc.date.created | 2025-06-21 | |
| dc.description.abstract | Objetivo: Determinar el impacto de la implementación de Guías de Práctica Clínica (GPC) en la mortalidad por enfermedad cardiovascular (ECV) en Colombia, durante el periodo comprendido entre 2007 y 2023. Materiales y métodos: Se llevó a cabo un estudio observacional, descriptivo basado en series temporales interrumpidas. Se analizaron todas las defunciones no fetales registradas por el Departamento Administrativo Nacional de Estadística (DANE), las cuales estuvieron anonimizadas, entre los años 2007 y 2023, y corresponden a causas básicas clasificadas bajo los códigos I20 a I25 de la Clasificación Internacional de Enfermedades, décima revisión (CIE-10), que agrupan las enfermedades isquémicas del corazón. Se calcularon tasas crudas de mortalidad y tasas estandarizadas por edad por 100.000 habitantes (TEE), con el objetivo de observar tendencias temporales ajustadas. Para evaluar cambios significativos en dichas tasas a lo largo del tiempo y especialmente teniendo en cuenta el año de referencia (2014), se empleó un modelo de promedio móvil integrado autoregresivo (ARIMA). Resultados: Durante el periodo de estudio se registraron 628.122 fallecimientos atribuidos a enfermedades cardiovasculares en Colombia. La mayoría de los decesos ocurrieron en hombres y en personas mayores de 60 años. La TEE disminuyó progresivamente de 61,8 por 100.000 habitantes en 2007 a 54,5 en 2023. Se observó una reducción estadísticamente significativa en la pendiente de la curva de mortalidad posterior al año 2014, año en el cual se consolidó la adopción nacional de las Guías de Práctica Clínica (GPC) para enfermedades cardiovasculares (-0,89; p=0,03). Conclusión: Se identificó una disminución sostenida en las tasas de mortalidad ajustadas por edad por ECV a partir del año 2014, lo cual coincide temporalmente con la implementación de GPC en Colombia. Sin embargo, persiste una brecha de género en la mortalidad, siendo los hombres los más afectados, por lo que deben implementarse estrategias para superar estos aspectos. Palabras clave: enfermedad cardiovascular, guía de práctica clínica, mortalidad, tendencias. | spa |
| dc.description.abstractenglish | Objective: To determine the impact of the implementation of Clinical Practice Guidelines (CPGs) on cardiovascular disease (CVD) mortality in Colombia between 2007 and 2023. Materials and methods: An observational, descriptive study based on interrupted time series was conducted. All non-fetal deaths recorded by the National Administrative Department of Statistics (DANE) between 2007 and 2023 were analyzed. These deaths were anonymized and corresponded to underlying causes classified under codes I20 to I25 of the International Classification of Diseases, Tenth Revision (ICD-10), which group together ischemic heart diseases. Crude mortality rates and age-standardized rates per 100,000 population (ERS) were calculated to observe adjusted time trends. To assess significant changes in these rates over time, and especially considering the reference year (2014), an autoregressive integrated moving average (ARIMA) model was used. Results: During the study period, 628,122 deaths attributed to cardiovascular disease were recorded in Colombia. Most deaths occurred in men and people over 60 years of age. The TER progressively decreased from 61.8 per 100,000 population in 2007 to 54.5 in 2023. A statistically significant reduction in the slope of the mortality curve was observed after 2014, the year in which the national adoption of Clinical Practice Guidelines (CPG) for cardiovascular diseases was consolidated (-0.89; p = 0.03). Conclusion: A sustained decline in age-adjusted mortality rates from CVD was identified starting in 2014, coinciding with the implementation of CPGs in Colombia. However, a gender mortality gap persists, with men being the most affected, so strategies must be implemented to address these issues. Keywords: cardiovascular disease, clinical practice guidelines, mortality, trends. | spa |
| dc.description.sponsorship | Universidad Libre Seccional Barranquilla - Facultad de Ciencias de la Salud Postgrados Médico Quirúrgicos - Especialización en Medicina Interna | spa |
| dc.format | spa | |
| dc.identifier.uri | https://hdl.handle.net/10901/31532 | |
| dc.relation.references | 1) Escobar G, Orozco A, Núñez J, Muñoz F. Mortalidad por Enfermedades Cardiovasculares en Colombia 1993-2017. Un análisis de las políticas públicas. Revista Salud Uninorte, 2020; 36(3): 558-570. | spa |
| dc.relation.references | 2) Padua G, Piñera W. Enfermedades no transmisibles. Tendencias actuales. Revista Cubana de Salud y Trabajo, 2024; 13(2): 50-54. | spa |
| dc.relation.references | 3) Pardo R, Molano V. Las guías de práctica clínica: una herramienta de participación en la construcción de una política pública. Acta Neurológica Colombiana, 2014; 30(4): 307-313. | spa |
| dc.relation.references | 4) Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. 2021; BMC public health; 21(1): 1-12. | spa |
| dc.relation.references | 5) Otto C, Nishimura R, Bonow R, Carabello B, Erwin III J, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 2021; 77(4): 450-500. | spa |
| dc.relation.references | 6) McMurray J, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence-based medicine. Circulation, 2021; 143(9): 875-877. | spa |
| dc.relation.references | 7) Ávila J, Bareño A, Castro J, Rojas C. Evaluación de la aplicación de las guías de hipertensión y diabetes en un programa de crónicos. Revista Med, 2014; 22(2): 58-67. | spa |
| dc.relation.references | 8) Muñoz O, García Á, Fernández D, Higuera A, Ruiz Á, Aschner P, et al. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: evaluación del riesgo cardiovascular. Revista Colombiana de Cardiología, 2015; 22(6): 263-269. | spa |
| dc.relation.references | 9) Aschner P, Muñoz O, Girón D, García O, Fernández D, Bohórquez L, et al. Guía de práctica clínica para la prevención, diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Colombia Médica, 2016; 47(2): 109-30. | spa |
| dc.relation.references | 10) Powell-Wiley T, Baumer Y, Baah F, Baez A, Farmer N, Mahlobo C, et al. Social determinants of cardiovascular disease. Circulation research, 2022; 130(5): 782-799. | spa |
| dc.relation.references | 11) Mensah G, Roth G, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J Am Coll Cardiol, 2019;74(20):2529–32. | spa |
| dc.relation.references | 12) Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–128 | spa |
| dc.relation.references | 13) Zou Z, Cini K, Dong B, Ma Y, Ma J, Burgner D, et al. Time trends in cardiovascular disease mortality across the BRICS: an age-period-cohort analysis of key nations with emerging economies using the global burden of disease study 2017. Circulation, 2020; 141(10): 790-799. | spa |
| dc.relation.references | 14) Rosengren A, Smyth A, Rangarajan S, Ramasundarahettige C, Bangdiwala SI, AlHabib KF, et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the prospective urban rural epidemiologic (PURE) study. Lancet Glob Health. 2019;7(6): e748–e60. | spa |
| dc.relation.references | 15) Smolina K, Wright FL, Rayner M, Goldacre M. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ. 2012; 344: d8059. | spa |
| dc.relation.references | 16) Sidney S, Quesenberry C, Jaffe M, Sorel M, Nguyen-Huynh MN, Kushi L, et al. Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol, 2016;1(5):594–9. | spa |
| dc.relation.references | 17) Jagannathan R, Patel SA, Ali M, Narayan K. Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors. Curr Diab Rep, 2019;19(7):44. | spa |
| dc.relation.references | 18) Walli-Attaei M, Joseph P, Rosengren A, Chow C, Rangarajan S, Lear S, et al. Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. The Lancet, 2020; 396(10244): 97-109. | spa |
| dc.relation.references | 19) Cortés L, Alvis L, Alvis N. Mortalidad por enfermedades cardiovasculares y su impacto económico en Colombia, 2000-2010. Revista Salud Uninorte, 2016; 32(2): 208-217. | spa |
| dc.relation.references | 20) Pérez M, Achcar J. Desigualdades socioeconómicas en la mortalidad por enfermedades cardiovasculares: Región Pacifico de Colombia, 2002-2015. Ciência & Saúde Coletiva, 2021; 26(1): 5201-5214. | spa |
| dc.relation.references | 21) Escobar G, Orozco A, Núñez J, Muñoz F. Mortalidad por Enfermedades Cardiovasculares en Colombia 1993-2017. Un análisis de las políticas públicas. Revista Salud Uninorte, 2020; 36(3): 558-570. | spa |
| dc.relation.references | 22) Liu L, Villavicencio F, Yeung D, Perin J, López G, Strong K, et al. National, regional, and global causes of mortality in 5–19-year-olds from 2000 to 2019: a systematic analysis. The Lancet Global Health, 2022; 10(3): e337-e347. | spa |
| dc.relation.references | 23) Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J Am Coll Cardiol. 2019;74: 2529–2532. | spa |
| dc.relation.references | 24) Roth GA, Mensah GA, Fuster V. The global burden of cardiovascular diseases and risks: a compass for global action. J Am Coll Cardiol. 2020;76: 2980–2981. | spa |
| dc.relation.references | 25) Mensah G, Sampson U, Roth G, Forouzanfar M, Naghavi M, Murray C, et al. Mortality from cardiovascular diseases in sub-Saharan Africa, 1990–2013: a systematic analysis of data from the global burden of disease study 2013. Cardiovasc J Afr. 2015;26(2 Suppl 1): S6–10. | spa |
| dc.relation.references | 26) Collaborators GBD, Ärnlöv J. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. The Lancet, 2020; 396(10258): 1160-1203. | spa |
| dc.relation.references | 27) Dai H, Much A, Maor E, Asher E, Younis A, Xu Y, et al. Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990–2017: results from the Global Burden of Disease Study 2017. European Heart Journal-Quality of Care and Clinical Outcomes, 2022; 8(1): 50-60. | spa |
| dc.relation.references | 28) Musinguzi G, Ndejjo R, Ssinabulya I, Bastiaens H, van Marwijk H, Wanyenze R. Cardiovascular risk factor mapping and distribution among adults in Mukono and Buikwe districts in Uganda: small area analysis. BMC Cardiovasc Disord. 2020;20(1):1–12. | spa |
| dc.relation.references | 29) Nilson E, Da Silva E, Jaime P. Developing and applying a costing tool for hypertension and related cardiovascular disease: Attributable costs to salt/sodium consumption. The Journal of Clinical Hypertension, 2020; 22(4): 642-648. | spa |
| dc.relation.references | 30) Mora-Pabón G. Research on heart failure in Colombia, time to take a step forward. Rev Fac Med, 2018; 66(2):137-138. | spa |
| dc.relation.references | 31) Observatorio Nacional de Salud. Boletín ONS No.1 Diciembre 2013: Enfermedad cardiovascular: principal causa de muerte en Colombia, 2013. Tomado de: www.ins.gov.co, fecha de acceso: abril de 2024. | spa |
| dc.relation.references | 32) Pérez M, Achcar J. Desigualdades socioeconómicas en la mortalidad por enfermedades cardiovasculares: Región Pacifico de Colombia, 2002-2015. Ciência & Saúde Coletiva, 2021; 26(1): 5201-5214. | spa |
| dc.relation.references | 33) Escobar G, Orozco A, Núñez J, Muñoz F. Mortalidad por Enfermedades Cardiovasculares en Colombia 1993-2017. Un análisis de las políticas públicas. Revista Salud Uninorte, 2020; 36(3), 558-570. | spa |
| dc.relation.references | 34) Mohebi R, Chen C, Ibrahim N, McCarthy C, Gaggin H, Singer D, y cols. Cardiovascular disease projections in the United States based on the 2020 census estimates. Journal of the American College of Cardiology, 2022; 80(6): 565-578. | spa |
| dc.relation.references | 35) Alhuneafat L, Al Ta'Ani O, Ghanem F, Saleh S, Del Rio-Pertuz G, Arriola-Montenegro J, y cols. Assessing the cardiovascular disease impact across Latin America and the Caribbean. Journal of the American College of Cardiology, 2024; 83(13S): 2470-2470. | spa |
| dc.relation.references | 36) Mohebbi B, Sabouri M, Tol A. Application of health education and promotion theory-based interventions on patients with cardiovascular disease: A systematic review. Journal of Education and Health Promotion, 2021; 10(1): 236. | spa |
| dc.relation.references | 37) Prabhakaran D, Jeemon P, Sharma M, et al.: The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health, 2018, 6:1339-1351. | spa |
| dc.relation.references | 38) Moran A, Forouzanfar M, Roth GA, et al.: Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation, 2014, 129:1483-1492. | spa |
| dc.relation.references | 39) Sampasa H, Lewis R. Frequent use of social networking sites is associated with poor psychological functioning among children and adolescents. Cyberpsychology Behav Soc Netw, 2015, 18:380- 385. | spa |
| dc.relation.references | 40) ONU. World population prospects 2019: highlights, 2019. Tomado de: https://population.un.org/wpp/Publications/Files/WPP2019_10KeyFindings.pdf. Fecha de acceso: abril de 2024. | spa |
| dc.relation.references | 41) Barquera S, Pedroza A, Medina C, et al.: Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res, 2015, 46:328-338. | spa |
| dc.relation.references | 42) Burden of Disease. Our World Data, 2016. Tomado de: https://ourworldindata.org/burdenof-disease. Fecha de acceso: abril de 2024. | spa |
| dc.relation.references | 43) Virtanen M, Vahtera J, Singh-Manoux A, Elovainio M, Ferrie J, Kivimäki M. Unfavorable and favorable changes in modifiable risk factors and incidence of coronary heart disease: the Whitehall II cohort study. Int J Cardiol, 2018; 269:7-12. | spa |
| dc.relation.references | 44) Razo C, Welgan C, Johnson C, et al. Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study. Nat Med, 2022; 28:2056–2065. | spa |
| dc.relation.references | 45) Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med, 2021;385:1268–1279. | spa |
| dc.relation.references | 46) SPRINT Research Group, Lewis CE, Fine L, et al. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med, 2021;384: 1921–1930. | spa |
| dc.relation.references | 47) Safronenko V, Chesnikova A. Treatment of comorbid patients over 80 years old: focus at arterial hypertension (analysis of real clinical practice). Therapy, 2023; 9(8): 38-46. | spa |
| dc.relation.references | 48) Bibbins K, Chertow G, Coxson P, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med, 2010; 362:590–599. | spa |
| dc.relation.references | 49) Yin J, Zhu Y, Malik V, Li X, Peng X, Zhang F, et al. Intake of sugar-sweetened and low-calorie sweetened beverages and risk of cardiovascular disease: a meta-analysis and systematic review. Advances in Nutrition, 2021; 12(1): 89-101. | spa |
| dc.relation.references | 50) Altman E, Madsen K, Schmidt L. Missed opportunities: the need to promote public knowledge and awareness of sugar-sweetened beverage taxes. International journal of environmental research and public health, 2021; 18(9): 4607. | spa |
| dc.relation.references | 51) Colchero M, Rivera J, Popkin B, Ng S. In Mexico, evidence of sustained consumer response two years after implementing a sugarsweetened beverage tax. Health Aff (Millwood), 2017; 36:564–571. | spa |
| dc.relation.references | 52) Colchero M, Popkin B, Rivera J, Ng S. Beverage purchases from stores in Mexico under the excise tax on sugar sweetened beverages: observational study. BMJ, 2016;352:h6704. | spa |
| dc.relation.references | 53) Zhang Y, Pletcher M, Vittinghoff E, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. JAMA Cardiol, 2021; 6:1406–1413. | spa |
| dc.relation.references | 54) Braunwald E. How to live to 100 before developing clinical coronary artery disease: a suggestion. Eur Heart J. 2022; 43:249–250. | spa |
| dc.relation.references | 55) Braunwald E. Cholesterol: the race to the bottom. Eur Heart J, 2021;42:4612–4613. | spa |
| dc.relation.references | 56) Zhang Y, Ma R, Ban J, et al. Risk of cardiovascular hospital admission after exposure to fine particulate pollution. J Am Coll Cardiol. 2021;78: 1015–1024. | spa |
| dc.relation.references | 57) Al-Kindi S, Brook R, Biswal S, Rajagopalan S. Environmental determinants of cardiovascular disease: lessons learned from air pollution. Nat Rev Cardiol, 2020;17:656–672. | spa |
| dc.relation.references | 58) Bennett J, Tamura H, Parks R, et al. Particulate matter air pollution and national and county life expectancy loss in the USA: a spatiotemporal analysis. PLoS Med, 2019;16: e1002856. | spa |
| dc.relation.references | 59) World Health Organization. MPOWER package of data-driven tobacco control measures helps protect up to 5 billion lives. Tomado de: https://www.who.int/news-room/featurestories/detail/mpower-package-of-data-driventobacco-control-measures-helps-protect-up-to-5- billion-lives. Fecha de acceso: abril de 2024. | spa |
| dc.relation.references | 60) Lavie C, Laddu D, Arena R, Ortega F, Alpert M, Kushner R. Healthy weight and obesity prevention: JACC health promotion series. J Am Coll Cardiol, 2018;72:1506–1531. | spa |
| dc.relation.references | 61) Pareek M, Schauer P, Kaplan L, Leiter L, Rubino F, Bhatt D. Metabolic surgery: weight loss, diabetes, and beyond. J Am Coll Cardiol, 2018; 71:670–687. | spa |
| dc.relation.references | 62) Puska P, Jaini P. The North Karelia Project: prevention of cardiovascular disease in Finland through population-based lifestyle interventions. Am J Lifestyle Med, 2020;14:495–499. | spa |
| dc.relation.references | 63) Lee C, Heckman B, Dabelea D, et al. Effect of metformin and lifestyle interventions on mortality in the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care. 2021; 44:2775– 2782. | spa |
| dc.relation.references | 64) McCoy RG, Van Houten HK, Karaca-Mandic P, Ross JS, Montori VM, Shah ND. Second-line therapy for type 2 diabetes management: the treatment/benefit paradox of cardiovascular and kidney comorbidities. Diabetes Care, 2021;44: 2302–2311. | spa |
| dc.relation.references | 65) Beran D, Hirsch I, Yudkin JS. Why are we failing to address the issue of access to insulin? A national and global perspective. Diabetes Care. 2018; 41:1125–1131. | spa |
| dc.relation.references | 66) World Health Organization. WHO prioritizes access to diabetes and cancer treatments in new Essential Medicines Lists. Tomado de: https://www.who.int/news/item/01-10- 2021-who-prioritizes-access-to-diabetes-and-cancer-treatments-in-new-essential-medicines-lists. Fecha de acceso: abril de 2024. | spa |
| dc.relation.references | 67) Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet, 2015; 385: 1975–1982. | spa |
| dc.relation.references | 68) Heerspink H, Stefánsson B, CorreaRotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med, 2020; 383: 1436–1446. | spa |
| dc.relation.references | 69) Gasparrini A, Guo Y, Hashizume M, et al. Mortality risk attributable to high and low ambient temperature: a multicountry observational study. Lancet, 2015; 386:369–375. | spa |
| dc.relation.references | 70) Zhao Q, Guo Y, Ye T, et al. Global, regional, and national burden of mortality associated with nonoptimal ambient temperatures from 2000 to 2019: a three-stage modelling study. Lancet Planet Health, 2021;5: e415–e425. | spa |
| dc.relation.references | 71) Wood A, Kaptoge S, Butterworth A, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet, 2018; 391:1513–1523. | spa |
| dc.relation.references | 72) Allen L, Nicholson B, Yeung B, Goianada-Silva F. Implementation of non-communicable disease policies: a geopolitical analysis of 151 countries. Lancet Glob Health, 2020; 8:e50–e58. | spa |
| dc.relation.references | 73) Landrigan P, Fuller R, Acosta N, et al. The Lancet Commission on pollution and health. Lancet, 2018;391: 462–512. | spa |
| dc.relation.references | 74) Brown L, Lynch M, Belova A, Klein R, Chiger A. Developing a health impact model for adult lead exposure and cardiovascular disease mortality. Environ Health Perspect, 2020; 128:97005. | spa |
| dc.relation.references | 75) Torres A, Sarmiento O, Stauber C, Zarama R. The Ciclovia and Cicloruta programs: promising interventions to promote physical activity and social capital in Bogotá, Colombia. Am J Public Health, 2013;103: e23–e30. | spa |
| dc.relation.references | 76) Muñoz O, García Á, Fernández D, Higuera A, Ruiz Á, Aschner P, et al. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: evaluación del riesgo cardiovascular. Revista Colombiana de Cardiología, 2015; 22(6): 263-269. | spa |
| dc.relation.references | 77) Li Y, Cao G, Jing W, Liu J, Liu M. Global trends and regional differences in incidence and mortality of cardiovascular disease, 1990− 2019: findings from 2019 global burden of disease study. European Journal of Preventive Cardiology, 2023; 30(3): 276-286. | spa |
| dc.relation.references | 78) Saglietto A, Manfredi R, Elia E, D'Ascenzo F, Biondi G, Munzel T. Cardiovascular disease burden: Italian and global perspectives. Minerva Cardiology and Angiology, 2021; 69(3): 231-240. | spa |
| dc.relation.references | 79) Hessami A, Shamshirian A, Heydari K, Pourali F, Alizadeh R, Moosazadeh M, et al. cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. The American journal of emergency medicine, 2021; 46(1): 382-391. | spa |
| dc.relation.references | 80) Bhagavathula A, Shehab A, Ullah A, Rahmani J. The burden of cardiovascular disease risk factors in the Middle East: a systematic review and meta-analysis focusing on primary prevention. Current Vascular Pharmacology, 2021; 19(4): 379-389. | spa |
| dc.relation.references | 81) Bhattarai S, Aryal A, Pyakurel M, Bajracharya S, Baral P, Citrin D, et al. cardiovascular disease trends in Nepal–An analysis of global burden of disease data 2017. IJC Heart & Vasculature, 2020; 30(1): 100602. | spa |
| dc.relation.references | 82) Bakris G, Ali W, Parati G. ACC/AHA versus ESC/ESH on hypertension guidelines: JACC guideline comparison. Journal of the American College of Cardiology, 2019; 73(23): 3018-3026. | spa |
| dc.relation.references | 83) Grundy S, Stone N. 2018 American Heart Association/American College of Cardiology/multisociety guideline on the management of blood cholesterol–secondary prevention. JAMA cardiology, 2019; 4(6): 589-591. | spa |
| dc.relation.references | 84) Arnett D, Blumenthal R, Albert M, Buroker A, Goldberger Z, Hahn E, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019); 140(11): e596-e646. | spa |
| dc.relation.references | 85) Piepoli M, Abreu A, Albus C, Ambrosetti M, Brotons C, Catapano A, et al. Update on cardiovascular prevention in clinical practice: a position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. European journal of preventive cardiology, 2020; 27(2): 181-205. | spa |
| dc.relation.references | 86) Coutin M. Utilización de modelos ARIMA para la vigilancia de enfermedades transmisibles. Revista Cubana de Salud Pública, 2007; 33(2): 1-11. | spa |
| dc.relation.references | 87) López P, Gómez D, Martínez D, Abat M, Alhabib K, Avezum Á, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. The Lancet Healthy Longevity, 2023; 4(1): e23-e33. | spa |
| dc.relation.references | 88) Román C, Fernández M, Acevedo M, Alarcón G, Araya M, Barquín I, et al. Ejercicio: una herramienta clave en la prevención cardiovascular. Consenso de la Sociedad Chilena de Cardiología y Cirugía Cardiovascular y de la Sociedad Chilena de Kinesiología en Cardiología y Cirugía Cardiovascular. Revista chilena de cardiología, 2019; 38(2): 149-157. | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.coar | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.rights.license | Atribución-NoComercial-SinDerivadas 2.5 Colombia | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | spa |
| dc.subject | enfermedad cardiovascular | spa |
| dc.subject | guia de practica clínica | spa |
| dc.subject | mortalidad | spa |
| dc.subject | tendencias | spa |
| dc.subject.lemb | Impacto de la implementación de guía de practica clínica en la mortalidad por enfermedad cardiovascular en Colombia, 2007 - 2023 | spa |
| dc.subject.subjectenglish | cardiovascular disease | spa |
| dc.subject.subjectenglish | clinical practice guidelines | spa |
| dc.subject.subjectenglish | trends | spa |
| dc.title | Impacto de la implementación de guías de práctica clínica en la mortalidad por enfermedad cardiovascular en Colombia, 2007-2023. | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_7a1f | spa |
| dc.type.driver | info:eu-repo/semantics/bachelorThesis | spa |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
| dc.type.local | Tesis de Especialización | spa |
Archivos
Bloque de licencias
1 - 1 de 1
Cargando...
- Nombre:
- license.txt
- Tamaño:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: